111 related articles for article (PubMed ID: 26626406)
21. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Kenerson HL; Aicher LD; True LD; Yeung RS
Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
[TBL] [Abstract][Full Text] [Related]
22. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations.
Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M;
Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042
[TBL] [Abstract][Full Text] [Related]
23. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
24. Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention.
Wheless JW; Klimo P
J Child Neurol; 2014 Nov; 29(11):1562-71. PubMed ID: 24105488
[TBL] [Abstract][Full Text] [Related]
25. Establishment of Tsc2‑deficient rat embryonic stem cells.
Ito Y; Kawano H; Kanai F; Nakamura E; Tada N; Takai S; Horie S; Arai H; Kobayashi T; Hino O
Int J Oncol; 2015 May; 46(5):1944-52. PubMed ID: 25738543
[TBL] [Abstract][Full Text] [Related]
26. Role of TSC-mTOR pathway in diabetic nephropathy.
Inoki K
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S59-62. PubMed ID: 18926585
[TBL] [Abstract][Full Text] [Related]
27. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
28. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.
Doğan V; Yeşil Ş; Kayalı Ş; Beken S; Özgür S; Ertuğrul İ; Bozkurt C; Örün UA; Karademir S
J Trop Pediatr; 2015 Feb; 61(1):74-7. PubMed ID: 25344617
[TBL] [Abstract][Full Text] [Related]
29. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP
Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026
[TBL] [Abstract][Full Text] [Related]
31. Double trouble: when sonic hedgehog signaling meets TSC inactivation.
Bhatia B; Nahlé Z; Kenney AM
Cell Cycle; 2010 Feb; 9(3):456-9. PubMed ID: 20081363
[TBL] [Abstract][Full Text] [Related]
32. IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma.
Folgiero V; Miele E; Carai A; Ferretti E; Alfano V; Po A; Bertaina V; Goffredo BM; Benedetti MC; Camassei FD; Cacchione A; Locatelli F; Mastronuzzi A
Oncotarget; 2016 Aug; 7(33):52900-52911. PubMed ID: 27174915
[TBL] [Abstract][Full Text] [Related]
33. Favourable prognosis in medulloblastoma with extensive nodularity is associated with mitogen-activated protein kinase upregulation.
Jóźwiak J; Sontowska I; Bikowska B; Grajkowska W; Galus R; Roszkowski M
Folia Neuropathol; 2011; 49(4):257-61. PubMed ID: 22212915
[TBL] [Abstract][Full Text] [Related]
34. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
[TBL] [Abstract][Full Text] [Related]
35. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
36. Implication of active Erk in the classic type of human medulloblastoma.
Wlodarski PK; Boszczyk A; Grajkowska W; Roszkowski M; Jozwiak J
Folia Neuropathol; 2008; 46(2):117-22. PubMed ID: 18587705
[TBL] [Abstract][Full Text] [Related]
37. Targeting mTOR as a Therapeutic Approach in Medulloblastoma.
Aldaregia J; Odriozola A; Matheu A; Garcia I
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29932116
[TBL] [Abstract][Full Text] [Related]
38. Renal cell carcinoma associated with tuberous sclerosis complex (TSC)/mammalian target of rapamycin (MTOR) genetic alterations.
Argani P; Mehra R
Mod Pathol; 2022 Mar; 35(3):296-297. PubMed ID: 35046523
[No Abstract] [Full Text] [Related]
39. MiR-592 activates the mTOR kinase, ERK1/ERK2 kinase signaling and imparts neuronal differentiation signature characteristic of Group 4 medulloblastoma.
Paul R; Bapat P; Deogharkar A; Kazi S; Singh SKV; Gupta T; Jalali R; Sridhar E; Moiyadi A; Shetty P; Shirsat NV
Hum Mol Genet; 2021 Nov; 30(24):2416-2428. PubMed ID: 34274968
[TBL] [Abstract][Full Text] [Related]
40. Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.
Eterovic AK; Maher OM; Chandra J; Chen K; Huse J; Zaky W
J Natl Compr Canc Netw; 2018 Jun; 16(6):683-691. PubMed ID: 29891519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
